ABSTRACT
[This corrects the article DOI: 10.1007/s42081-022-00165-z.].
ABSTRACT
In urban areas, air pollution is one of the most serious global environmental issues. Using time-series approaches, this study looked into the validity of the relationship between air pollution and COVID-19 hospitalization. This time series research was carried out in the state of Kuwait; stationarity test, cointegration test, Granger causality and stability test, and test on multivariate time-series using the Vector Error Correction Model (VECM) technique. The findings reveal that the concentration rate of air pollutants ( O 3 , SO 2 , NO 2 , CO , and PM 10 ) has an effect on COVID-19 admitted cases via Granger-cause. The Granger causation test shows that the concentration rate of air pollutants ( O 3 , PM 10 , NO 2 , temperature and wind speed) influences and predicts the COVID-19 admitted cases. The findings suggest that sulfur dioxide ( SO 2 ), NO 2 , temperature, and wind speed induce an increase in COVID-19 admitted cases in the short term according to VECM analysis. The evidence of a positive long-run association between COVID-19 admitted cases and environmental air pollution might be shown in the cointegration test and the VECM. There is an affirmation that the usage of air pollutants ( O 3 , SO 2 , NO 2 , CO , and PM 10 ) has a significant impact on COVID-19-admitted cases' prediction and its explained about 24% of increasing COVID-19 admitted cases in Kuwait.
ABSTRACT
OBJECTIVES: To assess the effectiveness and safety of tocilizumab, a humanised anti-interleukin-6 receptor antibody, in the treatment of critical or severe coronavirus disease 2019 (COVID-19) patients. METHODS: This was a retrospective cohort study of severe or critical COVID-19 patients (≥18 years) admitted to one hospital in Kuwait. Fifty-one patients received intravenous tocilizumab, while 78 patients received the standard of care at the same hospital. Both groups were compared for clinical improvement and in-hospital mortality. RESULTS: The tocilizumab (TCZ) group had a significantly lower 28-day in-hospital mortality rate than the standard-of care-group (21.6% vs. 42.3% respectively; p = 0.015). Fifty-five per cent of patients in the TCZ group clinically improved vs. 11.5% in the standard-of-care group (p < 0.001). Using Cox-proportional regression analysis, TCZ treatment was associated with a reduced risk of mortality (adjusted hazard ratio 0.25; 95% CI: 0.11-0.61) and increased likelihood of clinical improvement (adjusted hazard ratio 4.94; 95% CI: 2.03-12.0), compared to the standard of care. The median C-reactive protein, D-dimer, procalcitonin, lactate dehydrogenase and ferritin levels in the tocilizumab group decreased significantly over the 14 days of follow-up. Secondary infections occurred in 19.6% of the TCZ group, and in 20.5% of the standard-of-care group, with no statistical significance (p = 0.900). CONCLUSION: Tocilizumab was significantly associated with better survival and greater clinical improvement in severe or critical COVID-19 patients.